 |
 |
 |
 |
 |
 |
|
|
ABIOMED Home > News > Fourteenth AbioCor Patient Passes AwayFrost & Sullivan's Circulatory Assist Device Technology Leadership Award Conferred on ABIOMED, Inc. |
||||||||||||
 |
||||||||||||||
| Fourteenth AbioCor Patient Passes Away | ||||||||||||||
| Danvers,
Mass., November 5, 2004 -- ABIOMED, Inc. (NASDAQ: ABMD) has
been informed by Drs. Laman Gray and Rob Dowling, investigators for
the AbioCor® clinical trial at Jewish Hospital/University of Louisville,
that the 14th AbioCor patient passed away on November 4, 2004 as a
result of unrecoverable multi-organ failure. The device worked well
during his 166 days on support, with no malfunctions occurring.
The patient, William Wiley, 73, received the AbioCor on May 24, 2004 and was resident of Glasgow, KY. "We consider William to be a true hero who has made a significant contribution to advancing the care of patients with heart failure," said Dr. Dowling. "Our entire team is grateful to William and his family for the contribution they have made for patients," added Michael R. Minogue, President and CEO of ABIOMED. "We know this is a difficult time for the family and our thoughts and prayers are with them." Candidates for the AbioCor clinical trial must suffer from biventricular heart failure, be ineligible for heart transplantation and not able to be helped by any other available therapy, and have a high probability of dying in less than 30 days. In September, ABIOMED applied for initial FDA market approval this year for the AbioCor to treat a defined subset of irreversible end-stage heart failure patients under a Humanitarian Device Exemption. Based in Danvers, Massachusetts, ABIOMED, Inc. (pronounced "AB'-EE-O-MED") is a leading developer, manufacturer and marketer of medical products designed to assist or replace the pumping function of the failing heart. ABIOMED, which currently sells the BVS® 5000 Biventricular Support System and the AB5000™ Circulatory Support System, is the market leader in devices for the temporary support of patients with failing but potentially recoverable hearts. The company's AbioCor® Implantable Replacement Heart is the subject of an initial clinical trial being conducted under an Investigational Device Exemption from the United States Food and Drug Administration. The AbioCor has not been approved for commercial distribution, and is not available for use or sale outside of the initial clinical trial. ### Media Contact:
|
||||||||||||||
